Biography
Megan is an associate at Gilbert’s with a focus on intellectual property litigation. She has comprehensive trial and appeal experience in complex patent litigation, acting as counsel in patent infringement and validity matters before the Federal Court, Federal Court of Appeal, and Supreme Court of Canada. She also has a keen interest in copyright law, with experience in enforcing clients’ copyright rights in pre-litigation. Megan greatly enjoys working alongside scientists, clinicians, engineers, and creatives to craft strategies unique to the particular facts of each proceeding and the specific needs of each client.
Before joining Gilbert’s, Megan gained experience as an articling student and associate at another boutique intellectual property law firm specializing in pharmaceutical patent litigation.
Megan completed her JD at Osgoode Hall Law School in 2019. As a student Megan participated in Harold G. Fox Intellectual Property Moot, in which she finished as a semi-finalist in the oral rounds and won the Gordon F. Henderson Award for the best appellant factum. She has since had the pleasure of acting as a judge for the Fox Moot on several occasions. Megan also was a member of the Osgoode Innocence Project, during which she was involved in conviction ministerial review matters as well as civil litigation in respect of Crown disclosure.
Megan graduated from McMaster University in 2016 with a BHSc. (Honours) in Health Sciences, studying an eclectic mix of human biology, child health issues, and health policy. She credits the program’s unique inquiry-based learning as setting the foundation for her ability to distill large amounts of information down to discrete, bite-sized issues that can be tackled through research.
Outside of law, Megan enjoys watching films, reading, and hanging out with her husband and corgi.
Representative Cases
Pharmascience Inc. v Janssen Inc., (2022 FC 62, 2022 FC 1218, 2024 FCA 23, 2024 FCA 10, 2026 SCC 26): Successfully represented Janssen in patent infringement and validity proceedings with respect to Janssen’s schizophrenia long-acting injectable “INVEGA SUSTENNA” against the generic brand Pharmascience, with appeals in the Federal Court of Appeal and Supreme Court of Canada.
Janssen Inc. v Apotex Inc., (2022 FC 107, 2023 FC 912, 2023 FCA 253, 2024 FCA 9): Successfully represented Janssen in patent infringement and validity proceedings with respect to Janssen’s schizophrenia medication “INVEGA SUSTENNA” against the generic brand Apotex, with appeals in the Federal Court of Appeal.
Alexion Pharma v Amgen Canada (2025 FC 754): Successfully represented Janssen in a patent infringement and validity proceeding in respect of the biologic drug “SOLIRIS,” an antibody that treats rare blood disorders.
Janssen Inc. v Jamp Pharma Corp (2024 FC 816): Represented Janssen and Mitsubishi Tanabe Pharma Corporation in a patent infringement and validity action in respect of the diabetes drug “INVOKANA.” While the action was discontinued prior to trial, we successfully obtained an order compelling Jamp to provide samples for infringement testing.